BioGenCell News
10 articles
/PRNewswire/ -- BioGenCell, a biotechnology leader in regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
BioGenCell, a leader in regenerative medicine, has been granted Fast Track Designation by the FDA for its lead candidate, BGC101, aimed at treating severe Critical Limb Threatening Ischemia (CLTI). This designation allows for accelerated clinical development and compassionate-use access for eligible patients. BGC101 uses BioGenCells proprietary TRACT platform to create personalized cell therapies from a patients own blood, promoting tissue regeneration and restoring blood flow. The company has completed patient recruitment for its Phase 2 clinical trial, which focuses on amputation-free survival and symptom relief. This milestone highlights the potential of BioGenCells innovative approach to address unmet medical needs in CLTI.
BioGenCell pioneers revolutionary cell therapy for microvascular disease | CTech
BioGenCell, an Israeli biotech company, is developing a cell therapy treatment for microvascular diseases, a common and debilitating illness often resulting from advanced diabetes. The companys treatment combines immune and stem cell therapies to produce personalized cell treatments using the patients own blood. The treatment has shown promising results, with a 100% amputation-free survival rate in Phase 1 trials. The company, which has raised a total of $16 million, is currently raising funds for its Phase 3 trials and plans to expand its manufacturing capabilities globally.
InvestmentExpand
BioGenCell raises $16 million Seed round led by Marius Nacht for microvascular diseases treatment CTech
Israeli biotechnology company BioGenCell has completed a $16 million Seed round led by private investor Marius Nacht. The company develops technology for using stem cells from the patient’s own blood to treat microvascular diseases. Their current product is intended for the treatment of chronic limb-threatening ischemia (CLI) typically found in patients with diabetes and heavy smokers. BioGenCell recently received FDA approval permission to continue to Phase II clinical trials.
Investment
BioGenCell Ltd. appoints New Chair and Strengthens Board of Directors
Israeli stem cell co BiogenCell raises $1m
Stem cell start-up BiogenCell Ltd. has raised $1 million in funding. The company, founded a year ago, aims to treat blood flow problems in the limbs caused by diabetes and heart disease. BiogenCells unique product uses autologous cells derived from the patients themselves to repair blood vessels. The companys technology separates cells that have not yet undergone full cell speciation. BiogenCell is collaborating with physicians at Laniado Hospital in Netanya, Israel. The companys product is currently undergoing animal trials.
Investment
